Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells 21,258 Shares of Stock

Key Points

• Teva EVP Christine Fox sold 21,258 shares on April 30 at an average price of $35.31 for about $750,620, cutting her stake by 25.04% to 63,647 shares (valued ~ $2.25M).
• TEVA shares trade around $35.36 (52‑week range $14.99–$37.35) and Wall Street is largely bullish—nine Buy ratings vs. one Sell—with analysts raising targets and an average price target of $41.56.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) EVP Christine Fox sold 21,258 shares of the firm's stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $35.31, for a total value of $750,619.98. Following the transaction, the executive vice president owned 63,647 shares in the company, valued at $2,247,375.57. This represents a 25.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Christine Fox also recently made the following trade(s):

• On Thursday, March 5th, Christine Fox sold 7,924 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $31.67, for a total value of $250,953.08.

Teva Pharmaceutical Industries Stock Performance

Shares of TEVA stock traded up $0.41 during midday trading on Monday, hitting $35.36. The company had a trading volume of 7,444,270 shares, compared to its average volume of 8,293,405. The company's 50 day simple moving average is $31.15 and its 200 day simple moving average is $29.46. Teva Pharmaceutical Industries Ltd. has a 52-week low of $14.99 and a 52-week high of $37.35. The stock has a market cap of $40.65 billion, a price-to-earnings ratio of 26.58, a PEG ratio of 3.23 and a beta of 0.86. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. Research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on TEVA. The Goldman Sachs Group lifted their target price on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, February 9th. Truist Financial lifted their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday. UBS Group raised their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a "buy" rating in a report on Thursday. Piper Sandler reissued an "overweight" rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday. Finally, Jefferies Financial Group raised their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a "buy" rating in a report on Tuesday, January 6th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $41.56.

Institutional Trading of Teva Pharmaceutical Industries

Several large investors have recently bought and sold shares of TEVA. AQR Capital Management LLC grew its holdings in Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company's stock valued at $368,000 after purchasing an additional 4,732 shares during the last quarter. Focus Partners Wealth grew its holdings in Teva Pharmaceutical Industries by 4.5% in the first quarter. Focus Partners Wealth now owns 40,074 shares of the company's stock valued at $616,000 after purchasing an additional 1,739 shares during the last quarter. Franklin Resources Inc. acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at $255,000. Flow Traders U.S. LLC acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at $238,000. Finally, Cerity Partners LLC grew its holdings in Teva Pharmaceutical Industries by 2.9% in the second quarter. Cerity Partners LLC now owns 45,837 shares of the company's stock valued at $768,000 after purchasing an additional 1,291 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.